This content has neither been reviewed nor approved by MCG Health.

SHP Fecal Bacteriotherapy

AUTH: SHP Medical 181 (AC)

Link to Codes

MCG Health Ambulatory Care 26th Edition

- Coverage
- · Application to Products
- Authorization Requirements
- · Description of Item or Service
- · Exceptions and Limitations
- · Clinical Indications for Procedure
- Document History
- · Coding Information
- References
- Codes

Coverage

Return to top of SHP Fecal Bacteriotherapy - AC

See the appropriate benefit document for specific coverage determination. Member specific benefits take precedence over medical policy.

Application to Products

Return to top of SHP Fecal Bacteriotherapy - AC

Policy is applicable to all products.

Authorization Requirements

Return to top of SHP Fecal Bacteriotherapy - AC

Pre-certification by the Plan is required.

Description of Item or Service

Return to top of SHP Fecal Bacteriotherapy - AC

Fecal Bacteriotherapy is the transferring of healthy bacteria from donors' stool to a recipient's intestines to restore balance of bacteria needed for the immune system to fight infection.

Exceptions and Limitations

Return to top of SHP Fecal Bacteriotherapy - AC

- There is insufficient scientific evidence to support the medical necessity of fecal bacteriotherapy as it is not shown to improve health outcomes upon technology review for all of the following:
 - · Alcoholic hepatitis
 - · Alzheimer's disease
 - Autoimmune cholangiopathies (e.g., primary biliary cholangitis and primary sclerosing cholangitis)
 - Colon cancer
 - · Crohn's disease
 - D-lactic acidosis

- Diabetes
- Functional gastro-intestinal disorders (e.g., functional constipation, functional diarrhea, and functional dyspepsia)
- · Gastro-intestinal dysbiosis
- Graft-versus-host disease of the gut
- Hepatic steatosis
- · HIV infection
- · Idiopathic thrombocytopenic purpura
- Inflammatory bowel diseases
- Irritable bowel syndrome
- · Insulin resistance
- Intestinal multidrug-resistant bacterial decolonization
- Metabolic syndrome
- Multiple sclerosis
- Non-alcoholic fatty liver disease
- Obesity
- · Parkinson's disease
- Pouchitis
- Slow transit constipation
- Ulcerative colitis
- Urinary tract infection
- There is insufficient scientific evidence to support the medical necessity of Fecal Bacteriotherapy for uses other than those listed in the clinical indications for procedure section.

Clinical Indications for Procedure

Return to top of SHP Fecal Bacteriotherapy - AC

- · Fecal bacteriotherapy is considered medically necessary for ALL of the following
 - Individual with recurrent/drug resistant Clostridium Difficile
- Fecal Bacteriotherapy is NOT COVERED for ANY of the following
 - Alcoholic hepatitis
 - · Alzheimer's disease
 - Autoimmune cholangiopathies (e.g., primary biliary cholangitis and primary sclerosing cholangitis)
 - Colon cancer
 - · Crohn's disease
 - D-lactic acidosis
 - Diabetes
 - Functional gastro-intestinal disorders (e.g., functional constipation, functional diarrhea, and functional dyspepsia)
 - Gastro-intestinal dysbiosis
 - · Graft-versus-host disease of the gut
 - Hepatic steatosis
 - HIV infection
 - · Idiopathic thrombocytopenic purpura
 - Inflammatory bowel diseases
 - Irritable bowel syndrome
 - · Insulin resistance
 - Intestinal multidrug-resistant bacterial decolonization
 - Metabolic syndrome
 - · Multiple sclerosis
 - Non-alcoholic fatty liver disease
 - Obesity
 - · Parkinson's disease
 - Pouchitis
 - Slow transit constipation

- Ulcerative colitis
- Urinary tract infection

Document History

Return to top of SHP Fecal Bacteriotherapy - AC

- Revised Dates:Reviewed Dates:
- Effective Date: October 2022

Coding Information

Return to top of SHP Fecal Bacteriotherapy - AC

- · CPT/HCPCS codes covered if policy criteria is met:
 - CPT 44705 Preparation of fecal microbiota for instillation, including assessment of donor specimen
 - HCPCS G0455 Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen
- CPT/HCPCS codes considered not medically necessary per this Policy:
 - None

References

Return to top of SHP Fecal Bacteriotherapy - AC

References used include but are not limited to the following:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; Uptodate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

Fecal Microbiota Transplantation. (2018, Sep 10). Retrieved Sep 19, 2022, from The Infectious Diseases Society of America (IDSA): https://www.idsociety.org/search-results/?query=fecal%20microbiota#/fecal% 20microbiota/0/typeSort_na_int,score/desc/

Fecal microbiota transplantation for treatment of Clostridioides difficile infection. (2022, Aug 31). Retrieved Sep 19, 2022, from UpToDate: https://www.uptodate.com/contents/fecal-microbiota-transplantation-for-treatment-of-clostridioides-difficile-infection?search=fecal%

20microbiota&source=search_result&selectedTitle=1~45&usage_type=default&display_rank=1

Management of Clostridium difficile infection in inflammatory bowel disease (IBD). (2022). Retrieved Sep 19, 2022, from American Gastrointentinal Association (AGA): https://gastro.org/clinical-guidance/management-of-clostridium-difficile-infection-in-inflammatory-bowel-disease-ibd/

Codes

Return to top of SHP Fecal Bacteriotherapy - AC

CPT®: 44705 HCPCS: G0455

CPT copyright 2021 American Medical Association. All rights reserved.

MCG Health

Ambulatory Care 26th Edition